Novartis Announces the EU Approval of first-in-class Aimovig®️(erenumab) for Migraine Prevention
Novartis Announces the EU Approval of first-in-class Aimovig®️(erenumab) for Migraine Prevention
Shots:
- Results of 2600 patients trial reported significant i.e. ≥50% reduction in migraine days with comparable safety and tolerability to PBO
- Aimovig works by blocking calcitonin gene-related peptide receptor (CGRP-R) which plays vital role in migraine
- Can be self-administered every four weeks with the Sure Click®️ auto injector pen, device commonly used for different conditions
- Aimovig is already approved by FDA in May 17, followed by Australia and Swissmedic on July 3 & 13 respectively in 2018 with more expected approvals globally
